Figure 3 from Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Efficacy results in cohort F, BTC. A, Time on study treatment and treatment response per RECIST version 1.1 by BICR for participants with an objective response (confirmed CR or PR). B, Best percentage change from baseline in target lesion size per RECIST version 1.1 by BICR among participants with ≥1 postbaseline assessment. C, PFS per RECIST version 1.1 by BICR. D, OS. In B, percentage changes from baseline >100% are presented as 100%.
Fields of Study & Subjects
Cholangiocarcinoma and Gallbladder Cancer Studies
Gastric Cancer Management and Outcomes
Pancreatic and Hepatic Oncology Research
Publication details
- Publication date
- 26 March 2026
- Language
- EN